OBJECTIVE: This paper reports the results of risperidone treatment in seven patients (six adults and one adolescent) diagnosed as suffering from Prader-Willi syndrome (PWS) accompanied by severe behavioural disturbances. Risperidone was chosen following the failure of these patients to respond to other acknowledged modes of treatment for the psychiatric manifestations of PWS. METHOD: This was a prospective open-label study. Measures of Clinical Global Impression Scale (CGIS), Retrospective Overt Aggression Scale (ROAS), Aggression Score (AS) and weight were obtained during two baseline visits and again following 37 weeks of treatment with risperidone. RESULTS: Low dosages (1-3 mg/day; 1.6 mg/day on average) of risperidone brought about notable clinical improvement with no apparent adverse side effects. All measures evaluated--general behaviour, CGIS, OAS and weight--reacted favourably to the treatment protocol. CONCLUSION: The preliminary results presented here suggest that risperidone is useful in treating PWS due to its positive effect on the disruptive behavioural symptoms that accompany it.
OBJECTIVE: This paper reports the results of risperidone treatment in seven patients (six adults and one adolescent) diagnosed as suffering from Prader-Willi syndrome (PWS) accompanied by severe behavioural disturbances. Risperidone was chosen following the failure of these patients to respond to other acknowledged modes of treatment for the psychiatric manifestations of PWS. METHOD: This was a prospective open-label study. Measures of Clinical Global Impression Scale (CGIS), Retrospective Overt Aggression Scale (ROAS), Aggression Score (AS) and weight were obtained during two baseline visits and again following 37 weeks of treatment with risperidone. RESULTS: Low dosages (1-3 mg/day; 1.6 mg/day on average) of risperidone brought about notable clinical improvement with no apparent adverse side effects. All measures evaluated--general behaviour, CGIS, OAS and weight--reacted favourably to the treatment protocol. CONCLUSION: The preliminary results presented here suggest that risperidone is useful in treating PWS due to its positive effect on the disruptive behavioural symptoms that accompany it.
Authors: Karin B Jensen; Irving Kirsch; Moa Pontén; Annelie Rosén; Kathy Yang; Randy L Gollub; Vincent des Portes; Ted J Kaptchuk; Aurore Curie Journal: Neurology Date: 2017-04-19 Impact factor: 9.910
Authors: Jessica Duis; Pieter J van Wattum; Ann Scheimann; Parisa Salehi; Elly Brokamp; Laura Fairbrother; Anna Childers; Althea Robinson Shelton; Nathan C Bingham; Ashley H Shoemaker; Jennifer L Miller Journal: Mol Genet Genomic Med Date: 2019-01-29 Impact factor: 2.183
Authors: Helge Frieling; Christian K Eberlein; Maximilian Deest; Jelte Wieting; Maximilian Michael Jakob; Stephanie Deest-Gaubatz; Adrian Groh; Johanna Seifert; Sermin Toto; Stefan Bleich Journal: Orphanet J Rare Dis Date: 2022-08-26 Impact factor: 4.303